BioInvent International AB clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   BI-1206 in Combination With Rituximab With or Without…BI-1206 in Combination With Rituximab With or Without Acalabrutinib · Indolent B-Cell NHL

   Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2027

   BioInvent International AB·Phase 1/2· NCT03571568· Registry history of NCT03571568 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

2. Notable

   Different Doses of BI-1607 in Combination With Pembrolizumab and…Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, · Unresectable or Metastatic Melanoma

   Primary completion date changed from estimate of Dec 30, 2025 to Sep 9, 2026

   Also in this update: Trial sites reduced: 9 → 4 locations; Study completion pushed from Dec 30, 2025 to Jul 30, 2027

   BioInvent International AB·Phase 1/2· NCT06784648· Registry history of NCT06784648 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.